Skip to main content
Premium Trial:

Request an Annual Quote

CombiMatrix Increases Anticipated Net Proceeds from Public Offering to up to $12.2M

NEW YORK (GenomeWeb News) – CombiMatrix today raised the expected net proceeds from an intended public offering of its securities.

In a document filed with the US Securities and Exchange Commission, the company said that net proceeds from its proposed offering of 10,000 shares of Series D preferred stock is now estimated at up to $12.2 million, an increase from a previous estimate of up to $10.4 million.

The company said it expects net proceeds of $9.0 million from the sale of the units, and if the underwriter for the offering exercises its options in full, that figure would increase to $12.2 million.

Ladenburg Thalmann is the underwriter on the offering, which was originally disclosed by CombiMatrix in September. The company intends to offer 10,000 shares of Series D preferred stock and warrants to purchase up to a little more than 4.1 million shares of common stock. The proposed offering also includes about 4.1 million shares of common stock underlying the Series D preferred stock and 4.1 million shares of common stock issuable upon exercise of the warrants.

The Scan

Just Breathing

A new analysis suggests that most Mycobacterium tuberculosis is spread by aerosols from breathing, rather than by coughing, the New York Times reports.

Just Like This One

NPR reports that the World Health Organization has hired a South African biotech company to recreate mRNA vaccine for SARS-CoV-2 that is similar to the one developed by Moderna.

Slow Start

The Wall Street Journal reports that Biogen's Alzheimer's disease treatment had revenues for July through September that totaled $300,000.

Genome Research Papers on Cancer Chromatin, Splicing in the Thymus, Circular RNAs in Cancer

In Genome Research this week: analysis of bivalent chromatin sites, RBFOX splicing factors' role in thymic epithelial cells, and more.